{
    "nctId": "NCT03205033",
    "briefTitle": "Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy",
    "officialTitle": "Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.",
    "overallStatus": "COMPLETED",
    "conditions": "Sleep Disorders, Circadian Rhythm, Depression, Genotoxicity, Pain",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "To evaluate the response to melatonin as a sleep-wake rhythm synchronizer on the effects induced by chemotherapy in women with breast cancer.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female\n* Diagnosed with breast cancer\n* Indicated for the adjuvant treatment for breast cancer\n* Between 18 years and 75 years\n* Alphabetized\n\nExclusion Criteria:\n\n* Undergone chemotherapy or radiotherapy before inclusion in the study.\n* Pregnant\n* Epilepsy\n* Brain Stroke\n* Multiple sclerosis\n* BMI above 45 kg / m 2",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}